Equities Analysts Issue Forecasts for HSCS Q3 Earnings

Heart Test Laboratories, Inc. (NASDAQ:HSCS) – Investment analysts at Ascendiant Capital Markets issued their Q3 2025 earnings estimates for Heart Test Laboratories in a research report issued to clients and investors on Monday, January 20th. Ascendiant Capital Markets analyst L. Ward forecasts that the company will earn ($2.41) per share for the quarter. Ascendiant Capital Markets also issued estimates for Heart Test Laboratories’ Q4 2025 earnings at ($2.46) EPS, FY2025 earnings at ($9.82) EPS, Q1 2026 earnings at ($2.18) EPS, Q2 2026 earnings at ($2.11) EPS, Q3 2026 earnings at ($2.13) EPS, Q4 2026 earnings at ($1.93) EPS and FY2026 earnings at ($8.35) EPS.

Separately, Maxim Group restated a “buy” rating and set a $12.00 price objective on shares of Heart Test Laboratories in a research note on Wednesday, December 18th.

Heart Test Laboratories Stock Up 1.4 %

Shares of NASDAQ:HSCS opened at $3.50 on Wednesday. The business’s 50 day moving average is $3.44 and its 200 day moving average is $3.50. Heart Test Laboratories has a 12-month low of $2.36 and a 12-month high of $18.50. The stock has a market cap of $3.43 million, a price-to-earnings ratio of -0.44 and a beta of 2.90. The company has a quick ratio of 1.52, a current ratio of 1.72 and a debt-to-equity ratio of 0.01.

Heart Test Laboratories (NASDAQ:HSCS) last released its quarterly earnings data on Monday, December 16th. The company reported ($2.27) EPS for the quarter, beating the consensus estimate of ($2.30) by $0.03. During the same period in the prior year, the company posted ($15.92) EPS.

About Heart Test Laboratories

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.